A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults

Trial Profile

A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; IC 51
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 05 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 03 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top